Epidemiological and Clinical Presentation of Retinoblastoma among Nepalese Children in 2019

Author:

Limbu Ben1ORCID,Kafle Prerna Arjyal2,Lamichanne Diwa Hamal2,Pant Suresh Raj3,Shakya Samyek4,Rasaily Suresh B.K.4ORCID

Affiliation:

1. Department of Oculoplastic and Reconstructive Surgery, Tilganga Institute of Ophthalmology, National Academy of Medical Sciences, Kathmandu, Nepal

2. Department of Oculoplastic and Reconstructive Surgery, Biratnagar Eye Hospital, Biratnagar, Nepal

3. Department of Oculoplastic and Reconstructive Surgery, Geta Eye Hospital, Attariya, Nepal

4. Department of Vitreoretinal Surgery, Geta Eye Hospital, Attariya, Nepal

Abstract

Objectives Retinoblastoma (RB) is rare but potentially fatal if left untreated. This study aimed to evaluate the epidemiological profile, clinical manifestation, classification, and affordability of RB treatment among Nepalese children in the year 2019. Materials and Method A multicentric, multiethnic hospital-based cross-sectional study after ethical approval from the National Health Research Council was conducted from January 2019 to December 2019 by incorporating ophthalmologists all over the nation. Twenty-seven RB centers were selected. All the RB presented in the RB centers either newly diagnosed or ongoing treatment consented to the study were included and failed to consent for the study, RB survivors were excluded from the study. Data based on demographic profile, clinical manifestation, ethnical and geographical distribution, and treatment received were collected in the customized Google Form. Each case was classified at the time of diagnosis as per the International Classification of Retinoblastoma groups and different treatment modalities offered as per grouping and staging. The affordability of treatment was calculated using a catastrophic approach. Statistical Analysis Data were entered into Microsoft Excel 2010 and analyzed using Statistical Package for Social Sciences version 20. Result A total of 34 RB cases, 21 (61.76%) in ongoing treatment group and 13 (38.2%) in newly diagnosed group presented in the RB centers. Out of total, 32 (64.7%) had unilateral and 12 (35.3%) cases had bilateral involvement. The majority of patients was from Province 1 (35.3%) and belonged to the upper caste (38.2%). Leukocoria was the most common presentation (73.9%) followed by proptosis, red eye, and phthisis bulbi. More than 75% patients presented at advanced group D (54%) and E (21%) and stage 0 (90%). More than 90% of patients received systemic chemotherapy, and 42.6% received transpupillary thermotherapy. The average cost of RB treatment was estimated to be 521% of the nonfood expense of the family which is unaffordable to almost all cases (100%). Conclusion Leukocoria is the most common mode of clinical presentation in both unilateral and bilateral RBs. Early diagnosis and appropriate treatment are key to success for saving life, sight, and eye. However, community awareness programs against RB, active referral networks, and the establishment of chemotherapy centers with trained human resources are needed to reduce loss of life, sight, and eye.

Publisher

Georg Thieme Verlag KG

Subject

Cancer Research,Oncology

Reference33 articles.

1. Clinical presentation of retinoblastoma in Malaysia: a review of 64 patients;S C Reddy;Int J Ophthalmol,2010

2. “Retinoblastoma survival disparity”: the expanding horizon in developing countries;M Naseripour;Saudi J Ophthalmol,2012

3. Global retinoblastoma presentation and analysis by national income level;I D Fabian;JAMA Oncol,2020

4. Strategies to manage retinoblastoma in developing countries;G L Chantada;Pediatr Blood Cancer,2011

5. Retinoblastoma;H Dimaras;Lancet,2012

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Retinoblastoma and Its Masquerades;Egyptian Retina Journal;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3